Preterm babies given the monoclonal antibody palivizumab to prevent respiratory syncytial virus (RSV) also appear less likely to develop recurrent wheeze, at least until the age of six, according to new research.
Preterm babies given the monoclonal antibody palivizumab to prevent respiratory syncytial virus (RSV) also appear less likely to develop recurrent wheeze, at least until the age of six, according to new research.